Regulatory Signal: FDA Final Guidance — Incorporating Voluntary Patient Preference Information Over the Total Product Life Cycle | Federal Register, March 30, 2026 | Docket No. 2026-06063
On March 30, 2026, the FDA published final guidance titled "Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle," replacing the agency's August 2016 guidance on the same subject. The update is not a cosmetic revision. It expands the scope of where patient preference information (PPI) applies, raises the bar on how studies must be conducted, and — most importantly for this audience — signals that FDA now sees patient-derived data as a meaningful input across every stage of a device's regulatory life, from an IDE application all the way through postmarket enforcement decisions.
If your organization is preparing a premarket submission, pursuing Breakthrough Device designation, or managing postmarket obligations for a device that touches patients directly or affects their quality of life, you need to understand this guidance. Not because FDA is mandating anything new — PPI submission remains voluntary — but because the competitive and regulatory calculus around benefit-risk documentation just shifted in ways that will matter in your next submission.
What Patient Preference Information Actually Is
The FDA defines PPI as "qualitative or quantitative assessments of the relative desirability or acceptability to patients of specified alternatives" among health interventions. That definition is deliberately broad. PPI can include how patients weigh a device's risks against its benefits, which clinical outcomes they prioritize, how they value a reduction in one type of harm versus another, or whether they find a device's interaction modality acceptable given their daily life constraints.
What PPI is not: it is not patient complaint data, it is not adverse event reports, and it is not clinical trial outcome data — though it can inform how you frame and interpret all of those. PPI is specifically about patient preferences and values as an input to benefit-risk analysis. It asks the question: given what this device does and doesn't do, is the trade-off one that patients find acceptable?
That framing matters because it connects directly to how FDA evaluates benefit-risk profiles in premarket review. When a submission is close to the line — when the evidence base is genuinely contested or when a device addresses conditions with significant heterogeneity in patient experience — PPI data is precisely the kind of evidence that can tip a benefit-risk determination.
What Changed from 2016: A Decade of Scope Expansion
The 2016 guidance applied primarily to three premarket pathways: PMA applications, Humanitarian Device Exemption (HDE) applications, and De Novo classification requests. That was already a meaningful scope, but it left significant gaps. 510(k) submissions — by far the most common premarket pathway — were not addressed. Breakthrough Device designation requests were not addressed. IDE applications were not addressed. And postmarket contexts, from enforcement decisions to labeling changes, were outside the frame entirely.
The 2026 guidance closes all of those gaps. PPI now explicitly applies to:
- Investigational Device Exemption (IDE) applications
- Breakthrough Device designation requests
- Premarket Approval (PMA) applications
- Humanitarian Device Exemption (HDE) applications
- De Novo classification requests
- 510(k) premarket notification submissions
- Administrative, enforcement, and other FDA postmarket decisions
The inclusion of 510(k) submissions is significant. 510(k) is the primary pathway for the majority of Class II medical devices reaching the U.S. market. The 2016 guidance's silence on 510(k) created an implicit signal that PPI was a "high-risk device" concern. The 2026 guidance removes that implication entirely.
The postmarket and enforcement dimension is the most consequential expansion from a liability and quality management perspective. Patient preference data can now factor into how FDA views whether a device's risk profile justifies continued market access, or whether labeling changes are warranted. That is not a theoretical scenario — it has practical implications for how you build and maintain your postmarket surveillance program.
Beyond scope, the guidance also incorporates "pragmatic insights and addresses common questions" that emerged in the decade since 2016. Study conduct requirements have been tightened. Patient involvement in study design has been elevated from optional to recommended. FDA's expectations for when sponsors should seek pre-submission consultation have been clarified. And a new factor has been added to the list of situations where PPI is particularly useful: devices with subjective clinical endpoints.
The Four Objectives FDA Laid Out
The guidance is organized around four explicit objectives, each of which has direct implications for how manufacturers should approach PPI programs:
1. Encourage Voluntary PPI Submissions
FDA is signaling that it wants this data, even though it cannot require it. That signal matters. In my experience working with manufacturers on premarket submissions, "voluntary" guidance from FDA almost never stays truly optional at the practical level. When reviewers find PPI valuable in evaluating benefit-risk, submissions without it begin to look comparatively thin. Voluntary today can mean competitively disadvantaged tomorrow.
2. Outline Quality Standards for Well-Designed PPI Studies
The guidance establishes criteria for what makes a PPI study credible. This is the substance that most manufacturers need to pay attention to. FDA is not going to accept a quick patient survey assembled six weeks before submission. Well-designed PPI requires methodological rigor: representative patient populations, validated instruments, appropriate quantitative or qualitative methods matched to the research question, attributes that are mutually exclusive and clinically relevant, proper statistical handling, and documentation that follows professional standards such as those published by ISPOR (the International Society for Pharmacoeconomics and Outcomes Research).
Twelve quality attributes are described in the guidance as markers of a credible study. These range from patient-centeredness and clinical relevance to internal validity, heterogeneity consideration, and adherence to research standards. If your PPI study doesn't check these boxes, FDA may note its limitations in the decision summary — or simply not find it useful in its deliberations.
3. Provide Practical Recommendations for Collecting and Submitting PPI
The guidance gives manufacturers concrete direction on study administration, pre-submission consultation with FDA, and how to present PPI data in a submission. One of the notable procedural changes from 2016: non-self-administered PPI studies must now use trained research staff, not just any study personnel. And self-administered studies must include participant tutorials and comprehension quizzes before the survey is completed. These requirements exist to reduce cognitive bias and ensure that patients understand what they're being asked to evaluate.
The comprehension quiz requirement is particularly meaningful. It is a safeguard against a real problem in preference research: patients providing responses to questions they didn't actually understand, which produces data that looks quantitative but carries no real evidentiary weight. FDA is requiring that self-administered studies demonstrate participant comprehension before data collection begins.
4. Discuss How FDA Incorporates PPI into Decision Summaries and Device Labeling
This is the output side of the PPI equation. When FDA finds PPI data credible and relevant, it can incorporate it into the Summary of Safety and Effectiveness Data (SSED) for PMA approvals and into device labeling for certain device types. That labeling inclusion creates a new accountability layer. If your device's labeling reflects patient preference data that supported approval, your postmarket surveillance program needs to monitor whether real-world use outcomes are consistent with the preference data that supported the initial decision.
Which Devices Are Most Relevant
The guidance identifies categories of devices where PPI is particularly valuable. This is not an exhaustive list, and FDA is careful to note that PPI can be relevant across device types. But these categories are where the benefit-risk calculus is most likely to benefit from patient-derived preference data:
- Devices that directly interact with patients during use
- Devices providing health or aesthetic benefits
- Devices that materially affect quality of life
- High-risk or life-saving devices
- Devices addressing unmet medical needs or rare conditions
- Devices with subjective clinical endpoints (new in the 2026 guidance)
That last category is worth dwelling on. Subjective clinical endpoints — pain scales, functional capacity assessments, quality of life measures, patient-reported outcomes — are increasingly common in device clinical evidence packages, particularly for musculoskeletal, neurological, chronic pain, and behavioral health devices. When your primary clinical evidence relies on patient-reported outcomes, PPI data that validates how patients weight those outcomes is not supplementary evidence. It is directly correlated to the evidentiary core of your submission.
The rare disease and unmet medical need categories are equally important. For HDE applications, where FDA applies a different benefit-risk standard precisely because the patient population is small and alternatives are limited, patient preference data from that patient population can be determinative. A well-constructed PPI study that demonstrates patients' willingness to accept known risks in exchange for meaningful benefit — with no comparable alternative available — directly supports the benefit-risk finding FDA needs to make.
The "Voluntary But Strategically Valuable" Dynamic
I want to be direct about something that does not always get said plainly in regulatory circles: voluntary guidance items rarely stay competitively neutral over time.
Here is how this plays out in practice. FDA publishes guidance encouraging voluntary PPI submissions. Early adopters build PPI programs, submit data, and in some cases get their benefit-risk determinations strengthened by that data. Reviewers start referencing PPI in decision summaries. Those decision summaries become public records. Other manufacturers read them. The implicit standard in the submission landscape shifts. Within a few review cycles, submissions without PPI in applicable device categories start looking like they are missing something, even though nothing is technically required.
We saw this dynamic play out in the early years of the 2016 guidance with respect to PMA and De Novo submissions. Companies that invested in PPI programs early found themselves with a differentiated submission when benefit-risk was contested. Companies that waited often ended up scrambling to generate PPI data under time pressure, which is exactly the wrong environment for well-designed preference research.
The 2026 guidance accelerates that curve significantly. The expansion to 510(k) and the explicit inclusion of postmarket contexts means that PPI is no longer something only the PMA-track manufacturers need to think about. If you make a Class II device that meaningfully affects patient quality of life, this guidance is relevant to your regulatory strategy right now.
How PPI Maps to Your ISO 13485 QMS
For manufacturers operating under ISO 13485:2016, the concepts embedded in FDA's PPI guidance are not foreign — they map directly onto existing QMS requirements that you already have obligations to fulfill. The difference is that the 2026 guidance gives those requirements a new practical application.
Section 7.2 (Customer Requirements) and Section 8.2 (Customer Satisfaction)
ISO 13485 requires that you identify customer requirements, including patient requirements, and that you monitor and measure customer satisfaction. PPI is a structured, methodologically rigorous way to fulfill these requirements in a manner that FDA also finds credible. If your current customer satisfaction monitoring is limited to complaint forms and annual surveys, your QMS may be technically compliant but strategically weak. A well-designed PPI program produces the kind of patient-perspective data that satisfies ISO 13485 Section 7.2 and 8.2 obligations while simultaneously building the evidentiary record FDA wants to see in your submissions.
Risk Management Integration (ISO 14971)
Under ISO 14971:2019, your risk management process requires benefit-risk analysis. That analysis is only as strong as your understanding of what patients actually value and what trade-offs they find acceptable. PPI data directly strengthens the patient-perspective dimension of your risk-benefit documentation. If your ISO 14971 benefit-risk analysis currently relies entirely on clinician-derived benefit characterization, PPI provides a mechanism to bring the patient viewpoint into that analysis with the methodological rigor regulators expect.
This integration is particularly important for devices in the subjective endpoint categories mentioned in the guidance. If a patient-reported outcome measure is your primary endpoint, and your risk management file is built on a benefit characterization derived from clinical literature rather than from patient preference data, there is a gap. PPI closes that gap.
Design and Development (Section 7.3)
ISO 13485 Section 7.3 requires you to capture user needs and translate them into design inputs. PPI collected early in the device development lifecycle — before you have finalized design specifications — gives you documented patient-perspective inputs that can flow directly into your design history file. The guidance specifically recommends patient involvement in study design and implementation, which aligns with the voice-of-customer activities that should already be part of your design and development process.
If your design inputs are currently derived exclusively from clinical literature, clinician interviews, and engineering assumptions about what patients need, you have an opportunity to strengthen your DHF with patient-derived preference data that FDA reviewers will recognize as relevant evidence at the time of submission.
Post-Market Surveillance Linkages
The 2026 guidance's explicit inclusion of postmarket contexts creates a direct linkage between your PPI program and your post-market surveillance (PMS) obligations. If patient preference data supported your device's approval or clearance, your PMS program should include mechanisms to assess whether real-world outcomes remain consistent with the preferences and trade-off tolerances that patients expressed at the time of study. For manufacturers also pursuing EU market access under the EU MDR or IVDR, this PMS linkage aligns with the Post-Market Clinical Follow-Up (PMCF) requirements that the EU regulatory framework demands — creating a unified data collection architecture that serves both FDA and EU regulatory needs.
Building a PPI Program: Practical Starting Points
If your organization does not currently have a PPI program, the guidance's expansion creates an urgent reason to start building one. The key is to start before you are under submission pressure, because well-designed preference studies take time. Here is how I recommend approaching this for manufacturers at different stages.
For Manufacturers in Early Development
Incorporate patient preference research into your design and development plan as a formal activity under Section 7.3. Identify your patient population, define the relevant attributes and trade-offs your device presents, and engage a qualified researcher to help design a study methodology appropriate to your device type. Use the results as design inputs. This gives you documented patient-perspective evidence that serves multiple functions: it strengthens your design history file, it supports your ISO 14971 benefit-risk analysis, and it produces material you can include in a future premarket submission.
The guidance recommends early FDA engagement via the Q-Submission (pre-submission) pathway to discuss your PPI research questions, patient population, survey instruments, and recruitment strategy before you finalize your study design. For novel devices or complex benefit-risk situations, this consultation is worth pursuing. FDA's feedback on your proposed PPI methodology can prevent costly study redesigns later.
For Manufacturers Preparing a Premarket Submission
Conduct a rapid assessment of whether your device falls into one or more of the categories where FDA has indicated PPI is particularly valuable. If it does, evaluate whether existing published PPI literature is available for your device type or patient population. The guidance acknowledges that published research can be submitted if it is relevant and meets quality standards — you do not necessarily need to conduct a novel study from scratch.
If existing literature is insufficient, consider whether a rapid qualitative study — interviews or focus groups with patients from your intended use population — can generate meaningful preference data within your submission timeline. Qualitative data is explicitly contemplated by the guidance and does not require the same timeline as a full quantitative discrete choice experiment or conjoint analysis study.
For Manufacturers with Devices Already on the Market
The postmarket scope of the 2026 guidance creates a specific opportunity and risk for companies with cleared or approved devices. If your device is in a category where PPI is particularly relevant, consider whether your postmarket surveillance program should be expanded to include systematic patient preference data collection. This data serves two purposes: it builds the evidentiary record FDA could find relevant in future postmarket decisions, and it strengthens your EU MDR PMCF activities if you are also pursuing or maintaining CE marking.
At minimum, review your current PMS plan to confirm it includes mechanisms for capturing patient-perspective data beyond complaint records. A structured periodic patient survey, even a simple one, begins building the longitudinal preference data record that would be relevant in any future FDA postmarket review.
The MDUFA V and 21st Century Cures Context
This guidance fulfills a specific performance commitment FDA made in the Medical Device User Fee Amendments V (MDUFA V), which governs FDA device review operations for fiscal years 2023 through 2027. That context matters for two reasons. First, it means this guidance reflects a negotiated regulatory commitment, not a discretionary policy choice — FDA agreed to deliver this update as part of the fee arrangement that funds its device review program. The guidance is not going to be pulled back or substantially revised in the near term.
Second, MDUFA reauthorization comes up in 2027. Patient-focused development has been a bipartisan priority throughout multiple MDUFA cycles, beginning with the 21st Century Cures Act's push for patient-centered product development. As reauthorization approaches, there is every reason to expect that Congress will look at whether PPI integration has matured sufficiently to warrant stronger regulatory weight in device review. Companies that have built PPI programs under the current voluntary framework will be better positioned regardless of what the next legislative cycle produces.
What to Do Right Now
This guidance rewards early movers and penalizes companies that treat it as a future compliance consideration. Here are the concrete steps that manufacturers should take in the near term:
Assess your device portfolio against the PPI applicability criteria. For each device where your organization is active in premarket development or where postmarket surveillance obligations are ongoing, determine whether the device falls into one or more of the six applicability categories FDA identified. Document that assessment in your regulatory strategy files.
Review your ISO 14971 benefit-risk documentation. Identify whether your current benefit characterizations rely on patient-perspective data or exclusively on clinician and literature-derived inputs. For devices where subjective patient outcomes are central to the clinical evidence, this gap assessment is urgent.
Update your design and development procedures under ISO 13485 Section 7.3 to explicitly include patient preference research as a recognized design input activity. This does not require a major QMS overhaul — it requires adding PPI as a category of user needs evidence in your design and development planning records.
Identify a qualified research partner. PPI studies require expertise in health outcomes research, preference methodology, and study design that most device manufacturers do not have internally. Identifying and qualifying a research partner now — before you are under submission pressure — is a practical step that costs nothing upfront but eliminates a critical path dependency later.
For any active premarket program in an applicable device category, schedule a Q-Sub consultation with FDA to discuss your proposed PPI approach before finalizing your study design. The guidance explicitly encourages this, and early FDA feedback on your methodology prevents wasted investment.
Patient preference information has been part of the FDA device review landscape since 2016. The 2026 final guidance represents the maturation of that program into a full-lifecycle regulatory framework. Manufacturers who understand its implications now, and who begin building PPI into their development processes and quality management systems today, will have a meaningful advantage when they sit down to prepare their next submission.
About the Author
Jared Clark, JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, RAC is the Principal Consultant at Certify Consulting, where he has guided 200+ medical device manufacturers through FDA submissions, ISO 13485 certification, and regulatory strategy — with a 100% first-time audit pass rate over 8+ years of practice. Jared specializes in QMS strategy, technical documentation, and FDA regulatory compliance for medical device companies from startup to enterprise scale.
Last updated: April 10, 2026
Source: FDA Federal Register Final Guidance Notice, Docket No. 2026-06063, March 30, 2026
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.